The Korean journal of internal medicine

  • 제33권1호
  • /
  • Pages.28-35
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Changing treatment paradigms for the management of inflammatory bowel disease

  • Im, Jong Pil (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine) ;
  • Ye, Byong Duk (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, You Sun (Department of Internal Medicine, Inje University Seoul Paik Hospital) ;
  • Kim, Joo Sung (Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine)
  • 투고 : 2017.12.04
  • 심사 : 2017.12.12
  • 발행 : 2018.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

Inf lammatory bowel disease (IBD) is a chronic and progressive inf lammatory condition of the gastrointestinal tract causing bowel damage, hospitalizations, surgeries, and disability. Although there has been much progress in the management of IBD with established and evolving therapies, most current approaches have failed to change the natural course. Therefore, the treatment approach and follow-up of patients with IBD have undergone a significant change. Usage of immunosuppressants and/or biologics early during the course of the disease, known as top-down or accelerated step-up approach, was shown to be superior to conventional management in patients who had been recently diagnosed with IBD. This approach can be applied to selected groups based on prognostic factors to control disease activity and prevent progressive disease. Therapeutic targets have been shifted from clinical remission mainly based on symptoms to objective parameters such as endoscopic healing due to the discrepancies observed between symptoms, objectively evaluated inf lammatory activity, and intestinal damage. The concept of treat-to-target in IBD has been supported by population-based cohort studies, post hoc analysis of clinical trials, and meta-analysis, but more evidence is needed to support this concept to be applied to the clinical practice. In addition, individualized approach with tight monitoring of non-invasive biomarker such as C-reactive protein and fecal calprotectin and drug concentration has shown to improve clinical and endoscopic outcomes. An appropriate de-escalation strategy is considered based on patient demographics, disease features, current disease status, and patients' preferences.

키워드

과제정보

연구 과제 주관 기관 : Korea Centers for Disease Control and Prevention

참고문헌

  1. Raffals LE, Chang EB. Navigating the microbial basis of inflammatory bowel diseases: seeing the light at the end of the tunnel. Gut Liver 2016;10:502-508. https://doi.org/10.5009/gnl15491
  2. Kaplan GG, Ng SC. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313-321. https://doi.org/10.1053/j.gastro.2016.10.020
  3. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111-119. https://doi.org/10.5217/ir.2016.14.2.111
  4. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471-478. https://doi.org/10.1002/ibd.21417
  5. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-1363. https://doi.org/10.1002/ibd.22839
  6. Solberg IC, Cvancarova M, Vatn MH, Moum B; IBSEN Study Group. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflamm Bowel Dis 2014;20:60-68. https://doi.org/10.1097/01.MIB.0000436956.78220.67
  7. Yoon JY, Shin JE, Park SH, Park DI, Cha JM. Disability due to inflammatory bowel disease is correlated with drug compliance, disease activity, and quality of life. Gut Liver 2017;11:370-376. https://doi.org/10.5009/gnl16422
  8. Song HK, Lee KM, Jung SA, et al. Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res 2016;14:240-247. https://doi.org/10.5217/ir.2016.14.3.240
  9. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017;152:351-361. https://doi.org/10.1053/j.gastro.2016.09.046
  10. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008;371:660-667. https://doi.org/10.1016/S0140-6736(08)60304-9
  11. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-1201. https://doi.org/10.1053/j.gastro.2011.06.054
  12. Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease. A SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734-746. https://doi.org/10.1111/apt.13139
  13. Park SH, Yang SK, Park SK, et al. Long-term prognosis of Crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis 2014;20:488-494. https://doi.org/10.1097/01.MIB.0000441203.56196.46
  14. Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. J Crohns Colitis 2015;9:147-155. https://doi.org/10.1093/ecco-jcc/jju017
  15. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007;5:1430-1438. https://doi.org/10.1016/j.cgh.2007.09.002
  16. Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-1834. https://doi.org/10.1016/S0140-6736(15)00068-9
  17. Oh EH, Oh K, Han M, et al. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS One 2017;12:e0177479. https://doi.org/10.1371/journal.pone.0177479
  18. Kim JY, Park DI, Han DS, et al. Comparing the clinical outcomes of young-onset and adult-onset ulcerative colitis: a multi-center Korean Association for the Study for Intestinal Diseases study. Korean J Intern Med 2017;32:69-78. https://doi.org/10.3904/kjim.2014.262
  19. Park Y, Cheon JH, Park YL, et al. Development of a novel predictive model for the clinical course of Crohn's disease: results from the CONNECT study. Inflamm Bowel Dis 2017;23:1071-1079. https://doi.org/10.1097/MIB.0000000000001106
  20. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224. https://doi.org/10.1016/j.cgh.2008.06.010
  21. Froslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422. https://doi.org/10.1053/j.gastro.2007.05.051
  22. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1245-1255. https://doi.org/10.1016/j.cgh.2016.01.015
  23. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014;12:414-422. https://doi.org/10.1016/j.cgh.2013.06.019
  24. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-totarget. Am J Gastroenterol 2015;110:1324-1338. https://doi.org/10.1038/ajg.2015.233
  25. Kim ES, Chen M, Lee J, Lee CK, Kim YS. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res 2016;14:224-230. https://doi.org/10.5217/ir.2016.14.3.224
  26. Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016;65:408-414. https://doi.org/10.1136/gutjnl-2015-309598
  27. Wei SC, Chang TA, Chao TH, et al. Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:285-310. https://doi.org/10.5217/ir.2017.15.3.285
  28. Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017;152:362-373. https://doi.org/10.1053/j.gastro.2016.10.005
  29. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017.
  30. Yu Q, Mao R, Lian L, et al. Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intest Res 2016;14:322-332. https://doi.org/10.5217/ir.2016.14.4.322
  31. Park JJ, Yang SK, Ye BD, et al. Second Korean guidelines for the management of Crohn's disease. Intest Res 2017;15:38-67. https://doi.org/10.5217/ir.2017.15.1.38
  32. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-1417. https://doi.org/10.1016/S0140-6736(14)61908-5
  33. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology 2015;148:938-947. https://doi.org/10.1053/j.gastro.2015.01.026
  34. Eun CS. Is the therapeutic drug monitoring of anti-TNF agents necessary in Korean inflammatory bowel disease patients? Gut Liver 2017;11:3-4. https://doi.org/10.5009/gnl16574
  35. Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-1053. https://doi.org/10.1111/apt.14368
  36. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol 2017;15:1580-1588. https://doi.org/10.1016/j.cgh.2017.03.031
  37. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250-1256. https://doi.org/10.1038/ajg.2014.146
  38. Wu KC, Ran ZH, Gao X, et al. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. Intest Res 2016;14:152-163. https://doi.org/10.5217/ir.2016.14.2.152
  39. Williet N, Boschetti G, Fovet M, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol 2017;15:1750-1757. https://doi.org/10.1016/j.cgh.2016.11.023
  40. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12:720-727. https://doi.org/10.1038/nrgastro.2015.150
  41. Lee JW, Choi CH, Park JH, et al. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intest Res 2016;14:146-151. https://doi.org/10.5217/ir.2016.14.2.146
  42. Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res 2015;13:193-207. https://doi.org/10.5217/ir.2015.13.3.193
  43. Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology 2015;149:1716-1730. https://doi.org/10.1053/j.gastro.2015.08.055
  44. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70. https://doi.org/10.1053/j.gastro.2011.09.034
  45. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014;40:338-353. https://doi.org/10.1111/apt.12838

피인용 문헌

  1. Endoscopy in inflammatory bowel disease: from guidelines to real life vol.12, pp.None, 2018, https://doi.org/10.1177/1756284819865153
  2. Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/2090379
  3. Value-Based Health Care in Inflammatory Bowel Disease vol.25, pp.6, 2018, https://doi.org/10.1093/ibd/izy340
  4. NCoR1 Protects Mice From Dextran Sodium Sulfate–Induced Colitis by Guarding Colonic Crypt Cells From Luminal Insult vol.10, pp.1, 2018, https://doi.org/10.1016/j.jcmgh.2020.01.014
  5. Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis vol.32, pp.1, 2018, https://doi.org/10.1097/meg.0000000000001550
  6. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study vol.14, pp.1, 2018, https://doi.org/10.5009/gnl19023
  7. Early Intervention in Ulcerative Colitis: Ready for Prime Time? vol.9, pp.8, 2018, https://doi.org/10.3390/jcm9082646
  8. Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study vol.35, pp.5, 2018, https://doi.org/10.3904/kjim.2020.001
  9. Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization vol.2, pp.4, 2018, https://doi.org/10.1093/crocol/otaa080
  10. Fish oil supplementation enhances colon recovery after experimental colitis vol.163, pp.None, 2018, https://doi.org/10.1016/j.plefa.2020.102212
  11. Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators vol.64, pp.9, 2018, https://doi.org/10.5124/jkma.2021.64.9.596